new oral glp 1 agonist Will New Oral GLP-1 Agonists Be the Next Market Shaker?

Oral GLP-1 receptor agonists are generating a great deal of excitement as a potential inflection point in diabetes and obesity care. Amid the enthusiasm, however, a quieter and clinically important issue is

26.77

★★★★☆4.8 (126)

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

25.32

★★★★★4.9 (98)

Not an April fool's prank! The small molecule GLP-1 receptor agonist, orforglipron, has been approved by the FDA under the trade name, “Foundayo.” We discussed the data in a fall 2025 episode

29.50

★★★★★5.0 (157)

Aleniglipron: An Oral, Small Molecule GLP-1R Agonist Fast-Follower from Structure Therapeutics

29.32

★★★★★4.7 (84)

FDA Approved: Orforglipron (Foundayo) — Oral GLP-1 Drug • FDA approved for chronic weight management • Indicated for obesity and overweight with comorbidities • Oral, once-daily GLP-1 receptor agonist • First non-peptide

24.96

★★★★★4.9 (203)

NEW: This new oral GLP-1 could be a game-changer for people with type 2 diabetes. Click through to learn more about orforglipron and read the full story at https://diatribenews.org/4nO5ex7 💡 #diatribenews #T2D #

21.87

★★★★★5.0 (176)

Lesson: Oral Semaglutide: A New GLP-1 Receptor Agonist Product for the Treatment of Type 2 Diabetes

27.43

★★★★★4.8 (132)